Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,706 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) Clear all
Active, not recruiting Phase 2 Interventional

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

NCT06891066
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
ISL, ULO, BIC/FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Phase 2 Interventional Results available

Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)

NCT04295772
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02685020
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Phase 3 Interventional Results available

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

NCT03110380
View directory record Official record
Conditions
HIV-1-infection
Interventions
B/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
66
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Not applicable Interventional Results available

WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)

NCT04373551
View directory record Official record
Conditions
HIV-infection/AIDS
Interventions
Cultural adaptation of a patient-provider communication tool
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Phase 2 Interventional

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

NCT00001122
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 18, 2026, 2:58 AM EDT
Recruiting No phase listed Observational

Feasibility of HPV Testing With Mail-delivered Sample Collection Kits

NCT07087145
View directory record Official record
Conditions
HPV Infection, HIV Infections, HPV-Related Malignancy
Interventions
Mail-based Saliva Sample Kit, Study-related Surveys
Diagnostic Test · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Not applicable Interventional Results available

The Happy Older Latinos Are Active (HOLA) Health Promotion Study in HIV-Infected Latino Men

NCT03839212
View directory record Official record
Conditions
Human Immunodeficiency Virus, Cardiometabolic Risk
Interventions
HOLA Component 1, HOLA Component 2, HOLA Component 3, HOLA Component 4
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 18, 2026, 2:58 AM EDT
Terminated Phase 4 Interventional

Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin

NCT00194857
View directory record Official record
Conditions
Anemia, Neutropenia, Hepatitis C Virus, HIV Infections
Interventions
erythropoietin, GCSF
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants

NCT02275065
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Bictegravir, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Berkeley, California • Davis, California • Long Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience

NCT00487188
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Highly active antiretroviral treatment (HAART)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Cleveland, Ohio • Austin, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 18, 2026, 2:58 AM EDT
Terminated Phase 2 Interventional

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

NCT01026727
View directory record Official record
Conditions
HIV Infections
Interventions
MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2010 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

NCT02831673
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Phase 4 Interventional Results available

Kaletra Sex/Gender Pharmacokinetics (PK) Study

NCT00148759
View directory record Official record
Conditions
HIV Infections
Interventions
LPV/r
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 18, 2026, 2:58 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Impact of Hepatitis C Therapy and Bone Health

NCT03221582
View directory record Official record
Conditions
Human Immunodeficiency Virus, Hepatitis C
Interventions
EBR/GZR
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
40 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 18, 2026, 2:58 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma

NCT00686842
View directory record Official record
Conditions
Kaposi's Sarcoma
Interventions
VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
La Jolla, California • Los Angeles, California • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mobile Enhanced Prevention Support for People Leaving Jail

NCT04036396
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases, Bacterial, Hepatitis C, Substance Use Disorders
Interventions
Mobile Enhanced Prevention Support, Usual Care plus Customized Referrals
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Santa Fe Springs, California
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Health Problems Associated With Injection Drug Use

NCT01128920
View directory record Official record
Conditions
Intravenous Drug Abuse, HIV Infections
Interventions
Skin and Needle Hygiene Intervention, No intervention - assessment-only condition
Behavioral · Other
Lead sponsor
University of Northern Colorado
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Oct 18, 2026, 2:58 AM EDT
Terminated Phase 4 Interventional

Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

NCT00420355
View directory record Official record
Conditions
HIV Infection
Interventions
atazanavir, lopinavir/ritonavir
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 6, 2009 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Phase 3 Interventional

A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients

NCT00000991
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Dapsone, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
20
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Phase 2 Interventional

A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy

NCT00000820
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 18, 2026, 2:58 AM EDT
Completed No phase listed Observational

HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs

NCT00001103
View directory record Official record
Conditions
Cognitive Disorders, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Menlo Park, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Oct 18, 2026, 2:58 AM EDT
Completed No phase listed Observational

Neurodevelopmental and Neurological Study of Infants and Children With HIV-1 Infection and AIDS in Clinical Trials

NCT00000759
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 8 Years
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 2:58 AM EDT
Completed Phase 1 Interventional

Adoptive Transfer of Haploidentical NK Cells and N-803

NCT03899480
View directory record Official record
Conditions
Hiv, HIV Infections, Immune Deficiency
Interventions
Haploidentical Natural Killer (NK) Cells
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 18, 2026, 2:58 AM EDT